CAPTRUST Financial Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$58K	Buy	18,898 +1,790	+10%	+$6.92K	﹤0.01%	2886
2025 Q4	$70K	Buy	+17,108	New	+$84.7K	﹤0.01%	2649
2024 Q1	–	Sell	-419,721	Closed	-$4.14M	–	2570
2023 Q4	$4.14M	Buy	419,721 +6,407	+2%	+$45.7K	0.01%	615
2023 Q3	$3.16M	Buy	+413,314	New	+$4.12M	0.01%	679
2022 Q2	–	Sell	-161	Closed	-$1K	–	5109
2022 Q1	$1K	Buy	161 +141	+705%	+$1.5K	﹤0.01%	4738
2021 Q4	$0	Buy	+20	New	+$376	﹤0.01%	4890

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CAPTRUST Financial Advisors's RXRX Position: Q1 2026 in Review

CAPTRUST Financial Advisors increased its Recursion Pharmaceuticals (RXRX) stake by 10% in Q1 2026, buying an estimated $6.92K and bringing the position to 18,898 shares worth $58K. The position accounts for ﹤0.01% of the portfolio, ranked #2886.

CAPTRUST Financial Advisors first reported a position in RXRX in Q4 2021 and has held it in 6 quarters since. The position peaked at $4.14M in Q4 2023. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

CAPTRUST Financial Advisors held 18,898 shares of Recursion Pharmaceuticals worth $58K as of Q1 2026.
CAPTRUST Financial Advisors bought 1,790 Recursion Pharmaceuticals shares in Q1 2026, an estimated $6.92K.
Recursion Pharmaceuticals made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q1 2026, its #2886 holding.
CAPTRUST Financial Advisors first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 6 quarters since.
CAPTRUST Financial Advisors's Recursion Pharmaceuticals position peaked at $4.14M in Q4 2023.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.